Effects of ARBs on ambulatory blood pressure, glucose and lipid metabolism, and autonomic nerve function in hypertensive diabetic nephropathy patients

Effects of ARBs on ambulatory blood pressure, glucose and lipid metabolism, and autonomic nerve function in hypertensive diabetic nephropathy patients - Effects of ARBs on ambulatory blood pressure, glucose and lipid metabolism, and autonomic nerve function in hypertensive diabetic nephropathy patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000666

Enrollment

Registered

2008-11-01

Start date

2005-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, type 2 diabetes, diabetic nephropathy

Interventions

TL group: Start with once-daily dosing of telmisartan 40 mg, and dosage may be modulated accroding to the clinical parameters (telmisartan 20-80 mg/day). After 12 weeks telmisartan will be changed to

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes Mild-to-moderate hypertension (more than casual BP 130/85 or on antihypertensives) Urinary protein excretion more than 0.3 g/day Serum creatinine below 3.0 mg/dl Age above 18 years

Exclusion criteria

Exclusion criteria: 1) Pregnant women, or women suspected of being pregnant 2) Hyperkalemia 3) History of hypersensitivity to Telmisartan or Losartan 4) Severe liver disorder (losartan) 5) Severe biliary atresia or hepatic disorder (telmisartan)

Design outcomes

Primary

Measure	Time frame
1) Ambulatory blood pressure monitoring+: mean blood pressure, day-night variation, short-term blood pressure/heart rate variability, LF/HF 2) Renal function: creatinine clearance by Cockcroft-Gault method, urinary protein/albuminon excretion 3) Glucose metabolism: fasting blood glucose, fasting IRI, HOMA-IR. 4) Lipid metabolism: total cholesterol, LDL, HDL, MDA-LDA, oxidised cholesterol, small dense LDL, adiponectin. 5) Vascular function: ABI/baPWV, VEGF, HGF.	—

Measure

Time frame

1) Ambulatory blood pressure monitoring+: mean blood pressure, day-night variation, short-term blood pressure/heart rate variability, LF/HF 2) Renal function: creatinine clearance by Cockcroft-Gault method, urinary protein/albuminon excretion 3) Glucose metabolism: fasting blood glucose, fasting IRI, HOMA-IR. 4) Lipid metabolism: total cholesterol, LDL, HDL, MDA-LDA, oxidised cholesterol, small dense LDL, adiponectin. 5) Vascular function: ABI/baPWV, VEGF, HGF.

—

Countries

Japan

Contacts

Public ContactKazuaki UCHINO

Yokohama City University School of Medicine Department of Medical Science

uchinok@med.yokohama-cu.ac.jp045-787-2634

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026